114 related articles for article (PubMed ID: 30341858)
1. Results of Outcome of Two Pregnancies with Imatinib.
Shah S; Rohan B; Srinivas B; Snehal L
J Assoc Physicians India; 2018 Jan; 66(1):106. PubMed ID: 30341858
[No Abstract] [Full Text] [Related]
2. Chronic myeloid leukaemia in pregnancy: call for guidelines.
P P; Samal R; Ghose S
J Obstet Gynaecol; 2019 May; 39(4):582-583. PubMed ID: 30744447
[TBL] [Abstract][Full Text] [Related]
3. Breastfeeding in a patient with chronic myeloid leukemia during tyrosine kinase inhibitor therapy.
Terao R; Nii M; Asai H; Nohara F; Okamoto T; Nagaya K; Azuma H
J Oncol Pharm Pract; 2021 Apr; 27(3):756-760. PubMed ID: 32787559
[TBL] [Abstract][Full Text] [Related]
4. Emergence of del(20q) in a patient in molecular remission of chronic myelogenous leukemia during imatinib treatment, with reduction following imatinib discontinuation.
Numata A; Kajiyama R; Itabashi M; Ishii Y; Yamamoto W; Motohashi K; Matsumoto K; Hagihara M; Ishigatsubo Y; Fujisawa S
Leuk Lymphoma; 2016; 57(1):201-2. PubMed ID: 25860242
[No Abstract] [Full Text] [Related]
5. Pregnancy in patients with chronic myeloid leukemia treated with imatinib.
Yilmaz M; Demirhan O; Kuçukosmanoglu E; Pehlivan M; Okan V; Balat O; Pehlivan S
Leuk Lymphoma; 2007 Dec; 48(12):2454-6. PubMed ID: 18067024
[No Abstract] [Full Text] [Related]
6. What Happens When Imatinib Goes Generic?
McDougall J; Ramsey SD; Radich J
J Natl Compr Canc Netw; 2016 Feb; 14(2):128-31. PubMed ID: 26850483
[No Abstract] [Full Text] [Related]
7. Successful maintenance of molecular remission in chronic myelogenous leukaemia during pregnancy with transition from imatinib to pegylated interferon.
Ellis M; Mills AK
Intern Med J; 2015 Mar; 45(3):358-9. PubMed ID: 25735582
[No Abstract] [Full Text] [Related]
8. Does switching to a second-generation tyrosine kinase inhibitor or increasing imatinib dose have long-term benefits in chronic myeloid leukemia patients with suboptimal responses under upfront standard-dose of imatinib?
Eskazan AE; Tiribelli M
Leuk Res; 2018 Nov; 74():55-56. PubMed ID: 30296661
[No Abstract] [Full Text] [Related]
9. Imatinib--A New Tyrosine Kinase Inhibitor for First-Line Treatment of Chronic Myeloid Leukemia in 2015.
Gambacorti-Passerini C; Piazza R
JAMA Oncol; 2015 May; 1(2):143-4. PubMed ID: 26181011
[No Abstract] [Full Text] [Related]
10. Targeting Stem Cells in Chronic Myeloid Leukemia with a PPAR-γ Agonist.
Egan JM
N Engl J Med; 2015 Nov; 373(20):1973-5. PubMed ID: 26559576
[TBL] [Abstract][Full Text] [Related]
11. The Importance of Being Cured: A Chronic Myeloid Leukemia Perspective.
Raanani P
Acta Haematol; 2016; 135(3):131-2. PubMed ID: 26535978
[No Abstract] [Full Text] [Related]
12. Promyelocytic Blastic Crisis in Chronic Myeloid Leukemia During Imatinib Treatment.
Angriman F; Gutierrez Acevedo MN; Rossi MS; Gimenez Conca AD; Otero V; Arbelbide JA; Michelángelo H
Turk J Haematol; 2015 Jun; 32(2):193-4. PubMed ID: 26316496
[No Abstract] [Full Text] [Related]
13. Imatinib-treated chronic myeloid leukemia patients with discordant response between cytogenetic and molecular tests at 3 and 6 month time-points have a reduced probability of subsequent optimal response.
Bonifacio M; Binotto G; Maino E; Calistri E; Marin L; Scaffidi L; Frison L; De Marchi F; Krampera M; Semenzato G; Fanin R; Ambrosetti A; Tiribelli M;
Haematologica; 2015 Aug; 100(8):e299-301. PubMed ID: 25820333
[No Abstract] [Full Text] [Related]
14. Development of plasma cell leukemia in a patient with chronic myeloid leukemia while on treatment with imatinib mesylate.
Maral S; Bakanay SM; Yikilmaz AS; Dilek I
J Cancer Res Ther; 2018; 14(6):1431-1433. PubMed ID: 30488870
[TBL] [Abstract][Full Text] [Related]
15. Maternal, Fetal, and Neonatal Imatinib Levels With Treatment of Chronic Myeloid Leukemia in Pregnancy.
Burwick RM; Kuo K; Brewer D; Druker BJ
Obstet Gynecol; 2017 May; 129(5):831-834. PubMed ID: 28383372
[TBL] [Abstract][Full Text] [Related]
16. Twin pregnancy in a patient of chronic myeloid leukemia on imatinib therapy.
Meera V; Jijina F; Shrikande M; Madkaikar M; Ghosh K
Leuk Res; 2008 Oct; 32(10):1620-2. PubMed ID: 18420270
[TBL] [Abstract][Full Text] [Related]
17. Pregnancy outcomes in patients with chronic myeloid leukemia treated with imatinib mesylate: short report from a developing country.
Iqbal J; Ali Z; Khan AU; Aziz Z
Leuk Lymphoma; 2014 Sep; 55(9):2109-13. PubMed ID: 24237577
[TBL] [Abstract][Full Text] [Related]
18. [MET/ERK and MET/JNK Pathway Activation Is Involved in BCR-ABL Inhibitor-resistance in Chronic Myeloid Leukemia].
Tsubaki M
Yakugaku Zasshi; 2018; 138(12):1461-1466. PubMed ID: 30504658
[TBL] [Abstract][Full Text] [Related]
19. K356dup--an in-frame insertion in the BCR-ABL gene in an imatinib-resistant chronic myeloid leukemia.
Gniot M; Wasilewska EM; Lewandowski K
Int J Lab Hematol; 2012 Dec; 34(6):e3-6. PubMed ID: 25998099
[No Abstract] [Full Text] [Related]
20. Imatinib mesylate in chronic myeloid leukemia: frontline treatment and long-term outcomes.
Stagno F; Stella S; Spitaleri A; Pennisi MS; Di Raimondo F; Vigneri P
Expert Rev Anticancer Ther; 2016; 16(3):273-8. PubMed ID: 26852913
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
